GW Phar­ma walks away from ad­comm with unan­i­mous sup­port for an­ti-seizure med. An OK shouldn’t take long now

Any small doubts about GW Phar­ma’s $GW­PH chances for a quick OK for their land­mark, cannabis-based drug Epid­i­olex were quick­ly laid to rest to­day with a unan­i­mous vote in fa­vor of ap­proval from the ex­pert pan­el gath­ered to­day to of­fer their ad­vice.

The group vot­ed 13 to 0 in fa­vor of an OK, and FDA of­fi­cials help­ful­ly told the ad­comm mem­bers that they were com­mit­ted to giv­ing this ther­a­py an ac­cel­er­at­ed de­ci­sion. And they were backed by an in-house re­view at the FDA that al­so en­dorsed the drug on every ma­jor point, rec­om­mend­ing an ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER